As shown in Table 2 and Fig. 3, genetically proxied PCSK9 inhibition was associated with a reduced risk of prostate cancer (OR: 0.81; 95% CI 0.73–0.90; P = 4.52 × 10–5). This evidence concerns the gene PCSK9 and Familial prostate cancer.